Adjuvant Composition Skin Irritation Reduction

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current adjuvants for transdermal or transmucosal administration fail to sufficiently suppress skin irritation while effectively potentiating immunologic responses, especially when containing low molecular weight compounds.

Innovation Solution

An adjuvant composition comprising lauryl alcohol, propylene glycol, and glycerol, with specific mass ratios, is used for transdermal or transmucosal administration to minimize skin irritation and enhance immunologic response potentiation.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional adjuvants are used for transdermal or transmucosal administration, then immunologic response potentiation is achieved, but skin irritation is not sufficiently suppressed

Engineering Contradiction:
Improveimmunologic response potentiationVSAvoidskin irritation
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent uses a composite adjuvant system combining squalane (lipid component) with specific concentrations of propylene glycol (8-90% by mass) and glycerol (1-90% by mass). This composite formulation creates a synergistic effect where squalane provides immunostimulation while the glycol and glycerol components suppress skin irritation, resolving the contradiction between efficacy and safety

Inventive Principle:
Principle #40Composite materials

Solution Approach 2:

The patent optimizes the concentration parameters of propylene glycol (8-90% by mass) and glycerol (1-90% by mass) to achieve the desired balance. By adjusting these parameters within specific ranges, the formulation maintains immunologic response potentiation while suppressing skin irritation, demonstrating parameter optimization to resolve the technical contradiction

Inventive Principle:
Principle #35Parameter changes

2Ease of operation

If low molecular weight compounds are used in adjuvants, then transdermal absorption is improved, but skin irritation increases

Engineering Contradiction:
Improvetransdermal absorption efficiencyVSAvoidskin irritation
Core Design Contradiction:
Ease of operationVSObject-affected harmful factors

Solution Approach 1:

The patent uses squalane as an intermediary substance that facilitates transdermal absorption without causing irritation. Squalane acts as a mediator between the low molecular weight compounds (propylene glycol and glycerol) and the skin, enabling efficient absorption while the higher molecular weight squalane component buffers the irritating effects, allowing safe use of absorption-enhancing compounds

Inventive Principle:
Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The adjuvant composition effectively suppresses skin irritation and potentiates immunologic responses, as demonstrated by improved solubility and immunostimulation effects, even when administered separately from antigens, with enhanced safety and efficacy compared to conventional methods.

Implementation Method 1

an adjuvant composition for transdermal or transmucosal administration

Methodology Applied
Scientific EffectTransdermal absorption: Permeation

Data Source

PatentEP3064218B1Adjuvant composition
Publication Date: 2019.06.19 HISAMITSU PHARM CO INC

AI summary

An adjuvant composition of the present invention contains lauryl alcohol and propylene glycol. Contents of the lauryl alcohol and the propylene glycol are 0.5 to 25% by mass and 8.0 to 99.5% by mass, relative to the total mass of the adjuvant composition, respectively. The lauryl alcohol is dissolved, and the adjuvant composition is used for transdermal or transmucosal administration.